Reactions 1680, p198 - 2 Dec 2017
Hepatotoxicity and bone marrow suppression:
2 case reports
In a study of 30 patients, two patients [ages and sexes not
stated] were described, who developed hepatotoxicity and
hepatotoxicity with bone marrow suppression, respectively
during treatment with methotrexate and leflunomide.
The patients, who had a history of rheumatoid arthritis, were
undergoing treatment with methotrexate and leflunomide
[routes and dosages not stated] and subsequently, one patient
developed hepatotoxicity whereas, another patient developed
hepatotoxicity with bone marrow suppression [times to
reactions onsets not stated]. The patient’s methotrexate and
leflunomide were stopped. The patients condition returned to
normal within one month of methotrexate and leflunomide
Author comment: "Many Rheumatologists worldwide are
skeptical to use of this combination due to possible side
effects like hepatotoxicity and bone marrow suppression."
Doshi BS, et al. Study of efficacy and safety of methotrexate and leflunomide
combination therapy in patients with rheumatoid arthritis (RA)- An audit. Indian
Journal of Rheumatology 9 (Suppl.): S25-S26 abstr. P66, No. 5, Jul 2014.
Available from: URL: http://doi.org/10.1016/j.injr.2014.10.005 [abstract] -
Reactions 2 Dec 2017 No. 16800114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved